MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC.
| Autor: | Nassar, A.H., Adib, E., Kaldas, D., Feng, J., AbuAli, T., Aredo, J., Fitzgerald, B., Bar, J., Thummalapalli, R., Parikh, K., Whitaker, R., Chen, L., Harris, J., Ayanambakkam, A., Farid, S., Owen, D., Sharp, J., Velazquez, A.I., Ragavan, M., D'aiello, A. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS161-S161, 1p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|